Abstract
The effect of additional treatments after surgery in patients with primary cardiac sarcoma (PCS) remains unknown. The present study aims to evaluate the benefit of chemotherapy in patients with non-metastatic cardiac sarcomas after optimal resection. Between October 1979 and December 1995, 15 patients with a median age of 45 (range 16-66) and a resected primary cardiac sarcoma [angiosarcoma (six), malignant fibrous histiocytoma (three), leiomyosarcoma (two), rhabdomyosarcoma (two), liposarcoma (one) and synoviosarcoma (one)] received a doxorubicin-containing regimen within 6 weeks of surgery. Adjuvant chemotherapy combinations included cyclophosphamide, vincristine and dacarbazine in four patients; ifosfamide in nine; methotrexate and vincristine in one; and doxorubicin alone in one patient. At present, 13 patients have relapsed (five during therapy), with a median time to progression of 10 months. Twelve patients developed local relapse, in four cases without metastatic disease. Two patients remain in complete remission 27 and 25 months after surgery. The median time to progression was shorter in patients presenting a cardiac angiosarcoma than other histological types (3 vs 14 months, P < 0.01). Twelve patients have died, with a median overall survival of 12 months. The 2-year survival rate is 26%. Survival was significantly longer for patients with completely resected tumours (22 vs 7 months; P = 0.02) and those who did not have angiosarcoma (18 vs 7 months; P = 0.04). In conclusion, post-operative conventional doxorubicin-based chemotherapy failed to modify the natural history of patients with resected cardiac sarcomas. Locoregional failure remains the main problem even after histologically complete resection. New approaches must be tested in patients with primary cardiac sarcoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Llombart-Cussac, A., Pivot, X., Contesso, G. et al. Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer 78, 1624–1628 (1998). https://doi.org/10.1038/bjc.1998.733
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.733
This article is cited by
-
Cardiac synovial sarcoma masquerading as effusive constrictive pericarditis
Indian Journal of Thoracic and Cardiovascular Surgery (2023)
-
Perigraft hygroma mimicking recurrent angiosarcoma of the right atrium
General Thoracic and Cardiovascular Surgery (2022)
-
A case of primer angiosarcoma ın a young woman: lessons from multi-modality ımaging
The International Journal of Cardiovascular Imaging (2022)
-
Primary spindle cell sarcoma of heart: case report and review of literature
Indian Journal of Thoracic and Cardiovascular Surgery (2021)
-
Multidisciplinary approach to rare primary cardiac sarcoma: a case report and review
BMC Cancer (2019)